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ABSTRACT
 After unprecedented successes in B-cell malignancies, chimeric antigen 
receptor T cells have recently been investigated for the treatment of multiple 
myeloma. Chimeric antigen receptor targeting T cells B-cell maturation antigen 
(BCMA) on malignant plasma cells have led to impressive clinical responses in recent 
trials. However, BCMA-negative relapses have been observed, supporting the need for 
complementary treatment strategies. Here, we explored the feasibility of targeting 
CD138 (syndecan-1), a surface marker expressed on both normal and malignant 
plasma cells. We showed that T cells from both healthy donors and from multiple 
myeloma patients, when transduced with a CD138-specific chimeric antigen receptor, 
can eliminate tumor cell lines and primary myeloma cells both in vitro and in vivo. 
CD138 is also expressed by putative myeloma stem cells identified by Hoechst staining, 
and these cells can be eliminated by CD138-specific chimeric antigen receptor T 
cells. Preclinical analyses did not identify any on target off tumor cytotoxicity against 
normal epithelial or endothelial cells, further supporting the rationale for the use 
of adoptively transferred CD138-specific chimeric antigen receptor T cells for the 
treatment of patients with relapsed/refractory multiple myeloma. 
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INTRODUCTION
Multiple myeloma (MM) accounts for approximately 
17% of hematologic malignancies and 2% of all cancers 
in the United States [1–3]. Although the survival of MM 
patients has improved significantly over the past 15 years, 
most patients will continue to experience repeated relapses, 
with subsequent remissions becoming increasingly short, 
and will eventually succumb to refractory disease [4]. 
Malignant plasma cells are susceptible to cell-mediated 
immune targeting as evidenced by the graft-versus-
myeloma effect occurring after allogeneic hematopoietic 
stem cell transplantation [5]. Growing evidence also 
suggests that altered cellular immunity plays a role in 
the development of MM. Furthermore, targeting MM-
associated surface antigens with monoclonal antibodies 
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such as daratumumab [6] and elotuzumab [7], specific for 
CD38 and SLAMF7 (CS1), respectively, has proven to be 
a highly effective approach. Given evidence to support 
T-cell dysfunction in MM, the combination of antibody-
based therapies with immune modulators [8] also seems 
especially well-suited for this disease [9–11].
The clinical success of chimeric antigen receptor 
(CAR) T cells (CAR-Ts) in B-cell malignancies has 
reinvigorated the interest in developing CAR-Ts for MM. 
CAR molecules allow antibody mediated recognition 
of a targeted antigen to be combined with the cytotoxic 
and proliferative capacity of effector T cells, thereby 
overcoming several barriers to effective T cell responses, 
including the downregulation of MHC or costimulatory 
molecules and dysfunctional TCR signaling [12]. CD19-
specific CAR-Ts and κ-light chain specific CAR-Ts have 
been tested in MM with the goal of targeting plasma 
cell precursors, and have led to some clinical responses 
[13]. The most compelling clinical responses have been 
obtained with CAR-Ts targeting the B-cell maturation 
antigen (BCMA), with overall response rates over 80% in 
recent trials [14]. However, patients treated with BCMA-
specific CAR-Ts can relapse due to the emergence of 
tumor cells with low or absent BCMA expression [14]. 
Durable responses to CAR-T therapy for such patients 
will therefore require the targeting of additional surface 
antigens.
CD138 (syndecan-1) is a member of the syndecan 
family involved in cell-cell and cell-matrix interactions 
[15]. CD138 expression is a hallmark of both normal 
plasma cells and of MM tumor cells [15]. Importantly, 
CD138 appears to be involved in carcinogenesis, 
specifically in cell proliferation, angiogenesis, tumor 
invasion, and metastasis, making it an attractive target 
for CAR-T therapy. Indeed these features should prevent 
the occurrence of malignant cells lacking CD138 
expression [16]. The antibody-drug conjugate BT062 
(Biotest AG, Dreieich, Germany), comprising an anti-
CD138 chimerized antibody conjugated to the cytotoxic 
compound, maytansinoid, has been evaluated both as 
monotherapy, and in combination with either lenalidomide 
or pomalidomide and low-dose dexamethasone, and was 
shown to have an acceptable safety profile with preliminary 
evidence of activity in patients with relapsed/refractory 
MM [17–19]. The most common adverse events reported 
were diarrhea, fatigue, and nausea. CD138-specific 
CAR-Ts (CD138.CAR-Ts) have previously been tested 
in 5 patients with MM, also with an acceptable safety 
profile, and with some evidences of disease stabilization 
[20]. A remarkable response was also observed in a MM 
patient with extramedullary involvement [21]. Despite 
reaching initial clinical evaluation in this trial, the safety 
and efficacy of targeting CD138 with a CAR has not 
been explored in depth at the preclinical level. We have 
developed a CD138-specific CAR (CD138.CAR) using 
the single chain variable fragment (scFv) sequence 
derived from the BT062 chimeric antibody and have 
optimized the structure of this CAR to achieve optimal 
antitumor efficacy. Our preclinical assessment shows that 
the CD138.CAR-Ts we have developed display significant 
anti-MM activity both in vitro and in vivo, and are not 
likely to cause unacceptable on-target, off-tumor toxicity.
RESULTS
CD138.CARs are expressed by T cells from 
healthy donors
We have generated four CD138.CAR constructs, 
each encoding an identical scFv specific for CD138, 
but different hinges (IgG1.CH2.CH3, IgG1, CD8α), 
transmembrane domains (CD28, CD8α), and costimulatory 
endodomains (CD28, 4-1BB); these are referred to as 
CAR1, CAR2, CAR3, and CAR4 (Figure 1A). Expression 
of CARs was measured using flow cytometry with a Fab-
specific Ab. The transduction efficiency of the various 
CD138.CARs in blood mononuclear cells obtained from 
healthy individuals was consistently ≥50% (Figure 1B). 
The CD138.CAR-Ts expanded in vitro and, among the four 
engineered CARs, there were no significant differences in 
the composition of CD4+ versus CD8+ T cells or central/
effector memory T cells (Figure 1C).
CD138.CAR-Ts target CD138+ MM cell lines
To ensure that CD138.CAR-Ts targeted CD138+ 
MM cells, we used both standard 5-hour 51Cr release 
assays and 3 - 5 day co-culture assays. All CD138.CAR-
Ts generated from healthy donors, irrespective of the 
CAR construct, lysed the CD138+ MM cell lines OPM-
2, U266-B1, RPMI-8226, and MM.1S, at a significantly 
higher rate as compared to control T-cells (Ctr-Ts), while 
leaving CD138– targets (Raji) unaffected (Figure 2A, 2B). 
In the absence of cytokines, we then co-cultured CD138.
CAR-Ts and Ctr-Ts with the CD138+ MM cell lines OPM-
2, U266-B1, RPMI-8226, and MM.1S, or the CD138– 
tumor cells, Raji. Residual tumor cells were measured via 
flow cytometry analysis at day 3 - 5 of the co-culture. All 
CD138.CAR-Ts completely eliminated CD138+ tumor 
cells, while tumor cells overgrew in cultures with Ctr-
Ts (Figure 2C, 2D and Supplementary Figure 1A). No 
activity of CD138.CAR-Ts was observed against CD138– 
tumor cells. Analysis of co-culture supernatants collected 
after 24 hours showed the presence of Th1 cytokines when 
CD138.CAR-Ts were co-cultured with CD138+ tumor 
cells (Figure 2E, 2F and Supplementary Figure 1B). 
Lack of activity by CD138.CAR-Ts against 
normal epithelial and endothelial cells
CD138 has been reported to be expressed, based 
on IHC analysis, on the basolateral surface of some 
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mature epithelial cells, endothelial cells, and vascular 
smooth muscle cells [15]. With the same antibody used 
to evaluate CD138 expression by for flow cytometry in 
MM cell lines, we also assessed commercially available 
endothelial and epithelial cells for expression of CD138. 
All tested endothelial and epithelial cells were found to 
be negative for surface expression of CD138 by flow 
cytometry (Figure 3A). No measurable soluble CD138 
was found in the cell supernatants of these cells (Figure 
3B). Because CAR T cells are typically be infused 
in the context of lymphodepleting chemotherapy, we 
investigated whether such therapy could induce CD138 
expression  in endothelial cells. We found that neither 
drugs frequently used in the treatment of MM (e.g. 
melphalan, dexamethasone, and cyclophosphamide) nor 
drugs used as lymphodepleting agents prior to CAR-T 
administration (cyclophosphamide or fludarabine) 
upregulated the CD138 molecule (Supplementary 
Figure 2A). Finally, using a specific qPCR assay, we 
showed that CD138 mRNA transcript was expressed 
Figure 1: Characterization of CD138.CAR-Ts. (A) shows the schema of the CD138.CAR retroviral constructs (named CAR1, 
CAR2, CAR3 and CAR4) used to transduce activated T cells. (B) shows CD138.CAR expression evaluated by flow cytometry in control T 
cells (Ctr-Ts) and in T cells transduced with the four different CD138.CAR constructs. Upper panels are from one representative donor and 
lower graph shows cumulative data (n = 3-6). (C) shows the frequency of CD8 and and central memory subsets (CD45RA+CCR7+) gated 
on CD3+ cells for Ctr-Ts and CD138.CAR-Ts generated from healthy donors (n = 3-6). 
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at insignificant levels in endothelial and epithelial cells 
(Figure 3C). When evaluated in cytotoxicity assays, 
both CD138.CAR-Ts and Ctr-Ts exhibited negligible 
lysis of endothelial and epithelial cells (Figure 3D and 
Supplementary Figure 2B). Similarly, no elimination of 
endothelial or epithelial cells was observed in co-culture 
assays (Figure 3E and Supplementary Figure 2C) by 
CD138.CAR-Ts or Ctr-Ts, and there was no significant 
release of IFNγ (Figure 3F). We further confirmed 
the safety of CD138.CAR-Ts on gastrointestinal (GI) 
cells by co-culturing them with undifferentiated and 
differentiated adult GI stem cells. No significant amount 
Figure 2: CD138.CAR-Ts specifically lyse CD138+ target cells. (A) shows the results of standard 51Cr release assays for CD138+ 
cells (OPM-2 cells left panel) or CD138– tumor cells (Raji, right panel), at the indicted T cell (effector) to tumor cell (E:T) ratio. Symbols 
represent the mean  ±  SEM of CD138.CAR-Ts generated from 5 healthy donors (p < 0.0001, one-way ANOVA). (B) shows results of 
standard 51Cr release assays against other three CD138+ MM cell lines (U266, RPMI, MM.1S cells), at the 20:1 E:T ratio for Ctr-Ts or 
CD138.CAR-Ts (CAR1, CAR2, CAR3, and CAR4 are combined as no differences were observed between each CAR; 1-2 donors/each 
CAR). Each symbol represents a donor and the lines represent the mean and SEM for the groups. Shown are the p values of CD138.
CAR-Ts vs Ctr-Ts against each cell lines using a two-way paired t-test. (C) shows the percentage of residual tumor cells for CD138+ cells 
(OPM-2, left panel) or CD138– cells (Raji, right panel) co-cultured at 1:1 ratio with Ctr-Ts, or CD138.CAR-Ts. T cells and tumor cells were 
quantified by flow cytometry (p < 0.0001, one-way ANOVA). (D) shows the percentage of residual tumor cells using other CD138+ MM 
cell lines (U266, RPMI, MM.1S cells), in co-cultures with Ctr-Ts or CD138.CAR-Ts at 1:1 ratio. Shown are the p values of CD138.CAR-Ts 
(CAR1, CAR2, CAR3, and CAR4 are combined as no differences were observed between each CAR 1-2 donors for each CAR) vs Ctr-Ts 
against each cell lines using a two-way paired t-test. (E) shows the quantification of IFNγ released in the supernatant by Ctr-Ts or CD138.
CAR-Ts co-cultured for 24 hrs with CD138+ cells (OPM-2, left panel) or CD138– cells (Raji, right panel) at a 1:1 ratio, and quantified by 
CBA assays (p = 0.004, one-way ANOVA). (F) shows the quantification of IFNγ released in the supernatant for three additional CD138+ 
cell lines (U266, RPMI, MM.1S cells) by control T cells or by CD138.CAR-Ts (1–3 donors for each CAR). Shown are p value, paired 
t-test. p = ns indicates non-significant differences.
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Figure 3: Safety of CD138.CAR-Ts. (A) shows the expression of the CD138 by commercially available endothelial (right) or epithelial 
cells (left). Isotype control (of dermal cells for endothelial cells and colon cells for epithelial cells) and CD138 expression of OPM-2 cells 
are also included. (B) shows the evaluation of soluble CD138 in the supernatant of cultured cells using a specific ELISA assay. (C) shows 
the level of CD138 mRNA of cultured cells using qPCR. Data are shown as fold change as compared to the negative control (Raji). (D) 
shows the results of a standard 51Cr release assay of endothelial cells at the 40:1 E:T ratio by Ctr-Ts or CD138.CAR-Ts (CAR2, 3 and 4). 
Each symbol represents a donor and the lines represent the mean and SEM for the groups (Shown are p ns value, paired t-test.). (E) shows 
the evaluation of residual cells (CD138+ tumor cells, OPM-2 or commercially available epithelial or endothelial cells) when co-cultured 
at 1:1 ratio with Ctr-Ts or CD138.CAR-Ts (CAR 2 and 3 generated from healthy donors). Cells were quantified by flow cytometry. Each 
symbol represents a donor and the lines represent the mean and SEM for the groups. (F) shows the quantification of IFNγ released by 
Ctr-Ts or CD138.CAR-Ts co-cultured for 24 hrs with OPM-2 cells (positive CD138 control) or commercially available normal cells, and 
quantified by CBA assays (p = ns, one-way ANOVA). (G) shows the production of IFNγ in the supernatant of OPM-2 cells or differentiated 
adult gastrointestinal (GI) stem cells co-cultured with Ctr-Ts or CD138.CAR-Ts (CAR3). 
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of IFNγ was detected when CD138.CAR-Ts were 
exposed to differentiated (Figure 3G) or undifferentiated/
spontaneously differentiated (Supplementary Figure 2D) 
GI stem cells.
CD138.CAR-Ts can be generated from MM 
patients and target autologous CD138+ MM cells 
and putative MM cancer stem cells
We generated CD138.CAR-Ts from MM patients 
and tested them against MM cells collected from the same 
patients. Due to the limited number of available T cells 
and tumor cells from MM patients, we could not compare 
all constructs, and thus elected to transduce T cells only 
with CAR1. We reasoned that while other versions of 
CD138.CAR (e.g. CAR2 and CAR3) behaved superiorly, 
CAR1 activity on primary cells suggested that even a 
suboptimal CAR produces appropriate antitumor activity. 
Transduction efficiency of CAR-Ts (Figure 4A) and 
immune-phenotype composition mirrored that of healthy 
donors (Figure 4B). We also found a similar pattern of 
target specificity using both 51Cr release assays (Figure 
4C) and co-culture assays (Figure 4D). CD138.CAR-Ts 
released IFNγ and IL-2 in response to CD138+ MM cell 
lines (Figure 4E). 
When patient bone marrow aspirates infiltrated 
with malignant plasma cells were available, we tested 
CD138.CAR-Ts in an autologous setting. CD138+ cells 
were isolated from the bone marrow using microbeads 
and were co-cultured with CD138.CAR-Ts generated 
from the patients (autologous) or from healthy donors 
(allogeneic). Both allogeneic and autologous CD138.
CAR-Ts eliminated CD138+ myeloma cells (Figure 5A) 
and released Th1 cytokines (Figure 5B). Finally, to assess 
whether CD138.CAR-Ts can target putative MM stem 
cells, we used Hoechst staining to identify side-population 
(SP) cells in MM tumor cell lines and in bone marrow 
samples as a surrogate functional assay for cancer stem 
cells [22–25]. We detected SP cells in the RPMI-8221 
MM tumor cell line and thus co-cultured Ctr-Ts with 
RPMI-8226 MM cell line and found that both non-SP and 
SP cells were still present (73% ± 3.5% and 7% ± 6%, 
respectively), while CD138.CAR-Ts eliminated better both 
cell subsets (11% ± 5% and 0.05% ± 0.03%, respectively) 
(Figure 5C). We also directly sorted SP cells from RPMI-
8226 and cultured those with either Ctr-Ts or CD138.
CAR-Ts. SP cells from RPMI-8226 were eliminated only 
in the presence of CD138.CAR-Ts, and supernatant from 
these co-cultures showed the presence of Th1 cytokines 
(Figure 5D).
CAR.CD138-T cells are functional in xenograft 
models
 We assessed  the in vivo activity of CD138.
CAR-Ts in an NSG mouse-model of MM. All CD138.
CARs were tested in vivo despite their similar activity 
in vitro. CD138.CAR-Ts or Ctr-Ts were infused i.v. in 
mice engrafted 2 weeks earlier with OPM-2 MM cells 
transduced to express firefly luciferase. We selected the 
OPM-2 as the MM target in vivo since this tumor cell 
line lacks the expression of co-stimulatory molecules, 
while the other tumor cell lines retain the expression 
of either CD80 or CD86 (Supplementary Figure 3A). 
Tumors, monitored using in vivo bioluminescence 
(IVIS), grew rapidly in mice that received Ctr-Ts. In 
contrast, tumor growth was significantly delayed in mice 
receiving CD138.CAR-Ts (p = 0.04). However, CAR3-
expressing T cells showed superior control of tumor 
growth (Figure 6A and 6B) and better overall survival 
(p < 0.0001) (Figure 6C). Specifically, tumor free survival 
was superior for mice receiving T cells expressing CAR3 
(p = 0.026 as compared to CAR2). In addition, more mice 
treated with CAR3 (8 of 9 analyzed mice) had detectable 
T cells in the peripheral blood than mice treated with 
CAR2 (2 of 8) at the end of experiments, suggesting a 
better persistence of the former (Supplementary Figure 
3B). Of note, we confirmed that tumor isolated from 
mice with recurrent disease retained expression of CD138 
(Supplementary Figure 3C), excluding the possibility 
of antigen escape. To further demonstrate the clinical 
applicability of the proposed approach, we have generated 
a clinical grade PG13 retroviral packaging cell line and 
produced clinical grade supernatant encoding CAR3. As 
shown in Supplementary Figure 4, in the validation runs 
performed under Good Manufacture Practice (GMP), 
CD138.CAR-Ts maintained similar characteristics to 
those generated in preclinical experiments, including 
transduction efficiency, immune phenotype, expansion and 
cytotoxic activity. These data ensure the clinical feasibility 
of the proposed strategy in patients with MM.
DISCUSSION
CAR T cell-based therapy represents an appealing 
approach for MM, and initial clinical responses in patients 
treated with BCMA-specific CAR-Ts are encouraging 
[14]. However, relapse due to antigen-escape remains 
a challenge, and a comprehensive approach to CAR-T 
treatment in MM will thus necessitate the ability to target 
additional MM-associated surface antigens. Here we show 
that CD138 may represent a safe and effective target for 
CAR-T-based therapy of MM.
MM is characterized by genetic and phenotypic 
heterogeneities due to the presence of multiple subclones 
as the disease progresses [26]. This intrinsic heterogeneity 
mandates the need to explore additional targets in MM 
which will likely benefit from combination with BCMA-
specific CAR-Ts to prevent tumor escape. Previous 
clinical experience with monoclonal antibodies can 
guide antigen selection with the goal of anticipating or 
preventing life-threatening toxicities when the same 
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Figure 4: Function of CD138.CAR-Ts generated from MM patients. (A) shows the expression of the CAR.CD138 (CAR2) 
evaluated by flow cytometry in Ctr-Ts or CD138.CAR-Ts generated from 6 MM patients (p < 0.001, two-way paired t-test). (B) shows the 
immunophenotype of Ctr-Ts or CD138.CAR-Ts generated from MM pateints. Shown are p = ns value, paired t-test. (C) shows the results of 
a standard 51Cr release assay against CD138+ (OPM-2) or CD138– (Raji) tumor cell lines, at the indicted T cell to tumor cell ratio. Symbols 
represent the mean ± SEM of the Ts generated from 4 MM patients (p < 0.001, one-way ANOVA). (D) shows the percentage of tumor cells 
in experiments in which CD138+ cells (OPM-2, left) or CD138– cells (Raji, right) were co-cultured at 1:1 ratio with Ctr-Ts or CD138.CAR-
Ts. T cells and tumor cells were quantified by flow cytometry (p = 0.003, and p = ns, two-way paired t-test). (E) shows the quantification 
of IFNγ and IL-2 released by Ctr-Ts and CD138.CAR-Ts co-cultured for 24 hrs with CD138+ cells (OPM-2) at 1:1 ratio and quantified by 
CBA assays (p = 0.009 for IFNγ and p = 0.001 for IL-2, two-way paired t-test).
Oncotarget2376www.oncotarget.com
Figure 5: Targeting of primary MM tumors. (A) shows the percentage of residual MM tumor cells in experiments in which primary 
MM cells were co-cultured with autologous  (MM patients derived) or allogeneic (healthy donor derived) Ctr-Ts and CD138.CAR-Ts. T cells 
and malignant plasma cells were quantified by flow cytometry. Each symbol represents a donor and the lines represent the mean and SEM for 
the groups. Shown are the p values using a two-way paired t-test. (B) shows the quantification of IFNγ, and IL-2 released in the supernatant 
by Ctr-Ts or CD138.CAR-Ts generated from MM patients co-cultured for 24 hrs with autologous malignant plasma cells, and quantified by 
CBA assays. (C) shows the flow plots for two representative donors of Ctr-Ts or CD138.CAR-Ts co-cultured with CD138+ RPMI MM cell 
line. SP cells, non-SP cells and T cells at the end of the 3 days co-culture are shown. The graph on the right panel summaries the residual 
SP cells and non-SP cells in co-culture with CD138.CAR-Ts obtained from healthy donors (n = 2) and MM patients (n = 2). Shown are 
p value of two-way paired t-test. (D) shows the flow plots for two representative donors of Ctr-Ts or CD138.CAR-Ts co-cultured with SP 
cells sorted from the RPMI MM cell line. (E) shows the quantification of IFNγ and IL-2 released in the supernatant of Ctr-Ts or CD138.
CAR-Ts from 2 representative donors co-cultured with sorted SP cells, and quantified by CBA-assay.
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Figure 6: In vivo antitumor activity of CD138.CAR-Ts. NSG mice were engrafted with CD138+ OPM-2 cell line labeled with 
firefly (FF)-luciferase (4 × 106), and treated 2 weeks later with Ctr-Ts or CD138.CAR-Ts (1 × 107). (A) shows the bioluminescence signals 
(BLI) of Ctr-Ts and CD138.CAR-Ts. Each line shows the BLI for each mouse and the red dashed line the average of the BLI intensity 
for each group. (B) shows the fold expansion of BLI as compared to day 14 (day of T cell injection) summarized as average (± SEM). 
(C) shows the Kaplan-Meier survival curve [Ctr-Ts = 34 mice (T cells from a total of 7 donors); CAR1 = 17 mice (3 donors); CAR2 = 22 
mice (5 donors); CAR3=18 mice (4 donors); CAR4 = 10 mice (2 donors)]. 
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molecules are targeted via CAR T cells. For example, 
the CD38 and CS1 antigens, currently targeted with 
daratumumab and elotuzumab, respectively, in patients 
with relapsed/refractory MM, have been proposed for 
CAR-T-based therapy in MM, and are undergoing pre-
clinical assessment [27–30]. The rationale for other targets 
that have not been previously tested using monoclonal 
antibodies, such as the isoform variant 6 (CD44v6) 
[31, 32], CD70 [33–35], and APRIL [36] mainly draws 
from their expression in  a significant fraction of MM 
samples. However, each of these antigens not uniquely 
expressed by MM cells or plasma cells, and potential "on 
target off tumor" effects in patients will require careful 
assessment. In line with the goal of targeting MM-
associated antigens clinically validated with monoclonal 
antibodies, we have elected to assess the CD138 molecule. 
The CD138 antibody-drug conjugate (BT062), 
when used in patients with MM, was in general well 
tolerated, although mucositis, stomatitis, and diarrhea 
had occurred in some patients [17–19]. A group at the 
Chinese PLA General Hospital treated 5 MM patients 
with a CD138.CAR encoding 4-1BB, and showed some 
in vivo persistence of the CAR-Ts, and clinical responses 
in the absence of toxicity [20]. Although encouraging, 
these results must be interpreted with caution, due to the 
small sample size of the patient’s cohort and variability 
in responses. Here, we have provided further preclinical 
studies to support the safety and efficacy of targeting 
CD138. We observed that the CD138.CAR generated 
from the BT062 mAb, can be successfully expressed by 
autologous T cells and promote anti-MM activity in vitro 
and in vivo in a xenograft mouse model. The CD138.
CAR appears to be unaffected by soluble CD138, which 
may act as a decoy for CAR-Ts, because efficient killing 
occurs in co-culture with tumor cells lines that produce 
large amount of soluble CD138. Shedding of the antigen 
is not unique to CD138, and other CARs have been shown 
to retain their killing properties even in the presence of 
soluble antigen [37, 38]. Having systematically studied 
the other components (hinge, transmembrane domain and 
costimulation) of the CAR, we have also identified that, 
for the CD138.CAR, the combination of a short IgG1 
hinge and the 4-1BB co-stimulatory domain has superior 
in vivo efficacy despite similar activity in vitro, further 
underscoring the importance of careful and systematic 
analysis when constructing a new CAR.
MM is a malignancy in which putative cancer stem 
cells may play a critical role in causing tumor recurrence 
and drug resistance [39]. Targeting CD19 and the light-
chain of human immunoglobulins with CAR-Ts represent 
strategies to eliminate primitive B-cell precursors that may 
act as a reservoir of differentiated malignant plasma cells 
[13, 40, 41]. We used a functional Hoechst SP cell staining, 
previously validated to identify more primitive progenitors 
of hematopoietic stem cells and tumor cells [22, 24], as 
a surrogate marker of putative cancer stem cells in MM. 
We observed that SP cells express CD138, and can be 
effectively eliminated by CD138.CAR-Ts, strengthening 
the rationale that CD138.CAR-Ts will be effective in 
eliminating the reservoir of MM cancer stem cells.
Taking into consideration the observed mild toxicity 
associated with the anti-CD138 antibody-drug conjugate 
(BT062) and the potential amplification of these toxic 
effects  in the setting of CAR-T therapy, we have assessed 
the reactivity of CD138.CAR-Ts against human primary 
endothelial and epithelial cells, and observed no reactivity 
by CD138.CAR-Ts. Furthermore, because diarrhea 
was noted in patients treated with the BT062 antibody 
[17–19], we also explored the potential GI toxicity 
of targeting CD138 by evaluating the in vitro activity 
of CD138.CAR-Ts against GI stem cells (both 
undifferentiated and differentiated), and again observed 
no toxicity. Based on these data a new investigational 
new drug (IND) has been prepared to target CD138 with 
autologous CD138.CAR-Ts in patients with relapsed/
refractory MM, and the study is currently open for 
enrollment (ClinicalTrials.gov Identifier: NCT03672318). 
In conclusion, we provided efficacy and safety data 
supporting the clinical assessment of CD138.CAR-Ts in 
patients with MM. If safe and effective, CD138 could be 
combined with BCMA in an attempt to eradicate MM. In 
addition, to prevent antigen escape, future research should 
also take in consideration the microenvironment of MM 
that is enriched in immunosuppressive cells, cytokines 
and other soluble factors, like TGF-β or kynurenines that 
can potentially inhibit the antitumor activity of CAR-Ts 
[42]. Furthermore, the MM niche is highly hypoxic and 
hypoglycemic, and may limit the long-term efficacy of 
CAR-Ts [43]. All these elements will need to be clearly 
identified so that strategies to overcome such challenges 
can be successfully developed.
MATERIALS AND METHODS
Cell lines and human samples
The CD138+ MM-derived cell lines OPM-2, RPMI-
8226, U266-B1, MMS1 and the CD138– cell line Raji 
were obtained from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). All cells were maintained 
in culture with RPMI-1640 medium (Hyclone, Logan, 
Utah) containing 10% fetal bovine serum (FBS, Hyclone) 
and 2 mM L-glutamine (GIBCO-BRL, Gaithersburg, 
MD). Coronary, pulmonary and dermal endothelial 
cells and colon epithelial cells were purchased from 
ATCC and grown in the recommended media, following 
manufacturer’s instruction. Cells were kept in culture 
for less than 6 consecutive months, after which aliquots 
from the original expanded vial were used. Cells were 
maintained in a humidified atmosphere containing 5% 
CO2 at 37° C. Tumor cell lines were routinely tested to 
exclude contamination with mycoplasma and assessed 
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for the expression of CD138 to confirm identity. Buffy 
coats from healthy volunteer blood donors were obtained 
through the Gulf Coast Regional Blood Center, Houston, 
TX. Peripheral blood (PB) and bone marrow (BM) 
samples from de-identified patients with MM were 
collected according to local institutional review board 
(IRB) approved protocols (Baylor College of Medicine, 
Houston, TX). CD138+ cells from BM were isolated by 
immunomagnetic selection using paramagnetic beads 
specific for CD138 (Miltenyi), following manufacturer’s 
recommendation. In selected experiments, cells were 
treated with diluent or melphalan, dexamethasone, 
fludarabine or cytoxan for up to 72 hrs. 
Retroviral vectors
The CD138-specific single-chain variable fragment 
(scFv) was obtained from the human murine chimeric 
antibody specific for the human CD138 antigen (BT062) 
(patent US20090175863). The sequence of the scFv was 
codon optimized to enhance its translation in mammalian 
cells and cloned into CAR molecules [44]. All CAR 
constructs were subcloned into the SFG retroviral 
backbone. To produce the retroviral supernatant, 293T cells 
were co-transfected with Peg-Pam-e plasmid containing 
the sequence for MoMLV gag-pol, and the RDF plasmid 
containing the sequence for the RD114 envelope, using 
the Fugene6 transfection reagent (Roche Indianapolis, IN) 
as previously described [44]. The generation of retrovirus 
vectors encoding Firefly Luciferase gene (FFLuc) or the 
fusion protein eGFP-Firefly Luciferase (eGFP-FFLuc) 
have been previously described [44]. The FFluc specific 
vector, which also contains the puromycin resistance gene, 
was used for stable transduction of tumor cell lines. For 
GMP translational and validation studies a clinical grade 
packaging cell lines was generated by using the PG13 
packaging cell line cells (gibbon ape leukemia virus 
pseudotyping packaging cell line; CRL-10686, ATCC) as 
previously described [13]. We used the highest-titer clone 
to establish the master cell bank as recommended by FDA 
guidelines.
Generation of CD138.CAR activated T cells
Peripheral blood mononuclear cells (PBMCs) were 
isolated from 7 healthy volunteer blood donors and from 
6 MM patients by Lymphoprep (Accurate Chemical 
and Scientific Corp., Westbury, NY) density gradient 
centrifugation. Activated T cells were generated using 
immobilized CD3 and CD28 antibodies (Miltenyi), and 
transduced with CD138.CARs on RetroNectin (FN CH-
296; Takara, Otsu, Japan)-coated 24-well plate [44]. 
CD138.CAR transduced T cells (CD138.CAR-Ts) were 
then expanded in complete media (RPMI1640 [Hyclone] 
45%, Click’s medium [Irvine Scientific, Santa Ana, CA] 
45%, supplemented with 10% FBS and L-glutamine) 
containing recombinant human interleukin-2 (rhIL-2, 
100U/mL; Proleukine; Chiron, Emeryville, CA) or IL-7 
(10ng/ml; Peprotech, Rocky Hill, NJ) and IL-15 (5ng/ml; 
Peprotech), every 2–3 days as previously described [45]. 
As negative controls, T cells transduced with an empty 
vector were grown in parallel (control T cells, Ctr-Ts).
Immunophenotype 
We used phycoerythrin, fluorescein isothiocyanate, 
peridinin chlorophyll protein, allophycocyanin, Alexa-750, 
Alexa-700, Phycoerythrin Cyanin 7, Pacific Blue, or 
Krome-Orange-conjugated CD3, CD4, CD8, CD19, 
CD45RA, CD45RO, CCR7, CD138, CD31, CD80, 
CD86, CD83, CD40L, CD137L, OX40L, PD-L1 (Becton-
Dickinson-Pharmingen, San Diego, CA and Beckman 
coulter) monoclonal antibodies (Abs). We included 
control samples labeled with appropriate isotype Ab and 
used a “fluorescence minus one” strategy for multicolor 
staining. We used the Alexa Fluor 647-labeled AffiniPure 
F(ab’)2 Fragment Goat Anti-Mouse IgG, F(ab’)2 fragment 
specific (Jackson ImmunoResearch, West Grove, PA) to 
detect CD138.CAR expression in T cells. We analyzed 
cells using a FACScan (Becton-Dickinson) equipped with 
a filter set for 4 fluorescence signals, using CellQuest 
software, or a FACS-Canto II, using DIVA software. In 
some cases cells were collected using the Gallios Flow 
Cytometer (Beckman Coulter, Indianapolis, IN) and 
analyzed using FlowJo software version 9.3 (Tree Star, 
Ashland, OR) or Kaluza software (Beckman Coulter). 
Gastrointestinal stem cell differentiation and 
CAR-T co-culture
Adult duodenum stem cells and murine feeder cells 
were purchased from R&D (Minneapolis, MN). The 
expansion and differentiation of adult GI stem cell was 
performed following manufacturer’s instructions (MimEX 
GI kit, R&D). Undifferentiated and differentiated 
stem cells were then co-cultured with 5 × 105 Ctr-Ts, 
CD19.CAR-Ts or CD138.CAR-Ts, and 24 hours later 
supernatants were collected and the production of IFNγ 
was analyzed by using ELISA kit (R&D). The CD19.CAR 
was included to further ensure lack of activity due to a 
non-specific scFv. 
Hoechst SP cell staining
For Hoechst SP analysis, MM tumor cell lines and 
primary MM tumor cells were resuspended at 1×106 
cells/ml in pre-warmed media with 2% FBS and 10 mM 
HEPES (Sigma-Aldrich, St. Louis, MO). Hoechst 33342 
dye (Sigma) was added to a final concentration of 5 μg/
ml as previously described [22–24]. Cells were then 
incubated at 37° C for 105 minutes, washed in ice cold 
Hank’s buffered salt solution supplemented with 2% 
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FBS and 10 mM HEPES (HBSS+) and then immediately 
placed on ice. For analysis of the SP cell frequency, a 
live gate was defined by using the Hoechst red and blue 
axes to exclude dead cells (PI positive) and debris. For 
further phenotypic analyses, Hoechst labeled cells were 
subsequently stained with fluorescent-conjugated CD3 
and CD138 mAbs for 15 minutes on ice. Cells were then 
washed again and resuspended in ice cold HBSS+ buffer 
containing 2 μg/ml propidium iodide (PI; Sigma-Aldrich) 
for dead cell exclusion. Gates for SP and NSP cells were 
subsequently used to determine the expression of surface 
antigens using a BD LSRII analyzer (BD Bioscience). For 
the isolation of SP and NSP cells, we sorted them using 
a high-speed cell sorter (MoFlo, Dako Cytomation, Fort 
Collins, CO).
Evaluation of CAR-T cells function
To assess short-term cytotoxic activity we used a 
standard 51Cr release assay [44]. Chromum-51 labeled 
CD138+ and CD138- target cells were incubated with 
T cells at different effector to target ratios, and in 
medium alone or in 1% Triton X-100 (Sigma-Aldrich) 
to determine spontaneous and maximum 51Cr-release, 
respectively. The mean percentage of specific lysis 
of triplicate wells was calculated as follows: [(test 
counts − spontaneous counts)/(maximum counts − 
spontaneous counts)] × 100%. Coculture experiments 
were also performed. Control and CD138.CAR-Ts were 
cocultured in 24-well plates in the presence of CD138+ 
or CD138- target cells (at 1:1 E:T ratio) and in the 
absence of exogenous cytokines. Phenotypic analyses 
were performed on day 3 or 5 of coculture and T cells 
and tumor cells detected using CD3, CD138, or CD19 
Abs. We also cocultured T cells with autologous primary 
MM cells and with endothelial or epithelial cells. In the 
latter case, CD31 Ab was used to identify endothelial 
cells. Co-culture supernatant was harvested after 24 
hours of culture and cytokines measured using specific 
cytometric bead arrays (BD), or specific ELISAs (R&D 
System) according to manufacturer’s instructions. 
The soluble CD138 was also assessed in the culture 
supernatant of tumor cells using a specific ELISA kit 
(R&D System). 
Quantitative real-time PCR
To compare the mRNA levels of CD138 in different 
normal and multiple myeloma cell lines, > 1 × 106 cells 
were collected. Total RNA was isolated with RNeasy 
plus mini kit (Qiagen, Valencia, CA) and cDNA was 
synthesized with SuperScript VILO cDNA Synthesis Kit 
(Thermo Fisher) per manufacturer’s instructions. qRT-
PCR was performed on Quanta Studio 6 Flex (Applied 
Biosystem) with primers for CD138 (Taqman, Thermo 
Fisher) and β-actin (Taqman, Thermo Fisher) was used as 
an internal control. Each sample was performed in triplets 
and the relative amount of mRNA was quantified by using 
comparative Ct method. 
Xenogeneic mouse models
To evaluate the activity of CD138.CAR-Ts in vivo, 
6–8 wks old male and female NSG (NOD.Cg-Prkdc 
Il2rg/SzJ) mice were injected intravenously (i.v.) with 
the CD138+ tumor cell line OPM-2 labeled with FFLuc 
gene (4 × 106/mouse). Ten days later, mice received i.v. 
via tail vain either Ctr-Ts or CD138.CAR-Ts (1 × 107/
mouse). Tumor growth was monitored weekly by injecting 
mice intraperitoneally (i.p.) with D-luciferin (150 mg/kg). 
Photon emission was analyzed using the Xenogen-IVIS 
Imaging System as previously validated [44]. 
Statistical analysis
All in vitro data are presented as mean ± SEM, 
unless indicated. Student’s t-test was used to determine 
the statistical significance of differences between samples, 
and P < .05 was accepted as indicating a significant 
difference. For the bioluminescent experiments, intensity 
signals were log-transformed and summarized using mean 
±  SD at baseline and multiple subsequent time points for 
each group of mice. Changes in intensity of signal from 
baseline at each time point were calculated and compared 
using paired t-tests or Wilcoxon signed-ranks test. 
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